Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd.: Hong Kong Main Board IPO Application Lapsed, China’s Largest Temperature-Controlled Supply Chain Service Provider for Pharmaceutical & Life Science Industries
NewTimeSpace News: According to HKEX disclosures, the Hong Kong Main Board listing application submitted by Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. on 13 January 2026 has recently lapsed upon the expiry of the six-month validity period. CICC and Guojin Securities (Hong Kong) acted as joint sponsors at the time of filing. The Company ranks as China’s largest provider of temperature-controlled supply chain services for pharmaceutical and life science sectors, and the sole Chinese enterprise among the world’s top ten clinical trial temperature-controlled supply chain service providers.
NewTimeSpace News: Information published on the HKEX website shows that the Hong Kong Main Board listing application submitted by Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. on 13 January 2026 has recently lapsed after the six-month validity period expired. CICC and Guojin Securities (Hong Kong) served as joint sponsors upon submission.
Shengsheng Pharma Cold Chain is a leading integrated temperature-controlled supply chain service provider for the pharmaceutical and life science industries in China, with core focus on temperature-controlled supply chain services for clinical trials. According to reports by Frost & Sullivan, measured by 2024 revenue, the Company ranks first in China’s market for temperature-controlled supply chain services targeting pharmaceuticals and life sciences, and it is the only Chinese player among the global top ten clinical trial temperature-controlled supply chain service providers.
The Group delivers services covering the full lifecycle of medical products and has served more than 7,000 clients, including leading biopharmaceutical and biotechnology firms, central laboratories, CROs and CDMOs.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- SINOMAGS TECH Secures CSRC Filing Approval, Plans Issuance of Approximately 26.89 Million H-shares with Full Tradability Arrangement
- SHEIN: Secures CSRC Overseas Listing Filing Approval, Plans HK Main Board Listing via Offering Approximately 342 Million H-shares
- SSI NEW MATERIAL: Hong Kong Main Board IPO Application Lapsed, Ranking No.1 in Global Acoustic Enhancement Materials Market
- QDAMA: Hong Kong Main Board IPO Application Lapsed, China’s Largest Community Fresh Produce Chain Enterprise
- RelyEZ Energy Hong Kong Main Board IPO Application Lapsed, Ranking No.1 Global Provider of Full-Lifecycle Energy Storage Asset Solutions
